Biotech companies need to share highly confidential documents in parallel with multiple prospective licensing partners — some who may be competitors — while ensuring that none of these proprietary documents are compromised during the process.
Biotech companies need to share highly confidential documents in parallel with multiple prospective licensing partners — some who may be competitors — while ensuring that none of these proprietary documents are compromised during the process.